COMMUNIQUÉS West-GlobeNewswire

LiveWorld Launches LiveInsight AI™, Creating a New Category of Intelligence Systems for Pharma
03/06/2026
With 12 patents pending, the Human-Led, AI-Powered system delivers decision-grade insights — customized by disease state, brand, and user — in minutes, not weeks CAMPBELL, Calif. and NEW YORK, June 03, 2026 (GLOBE [...]
Porch Light Health Launches Porch Light Health University to Expand Access to Practical Addiction Medicine Training
03/06/2026
DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- Porch Light Health today announced the launch of Porch Light Health University (PLHU), a new educational platform designed to equip healthcare professionals with practical, real [...]
OneMedNet Surpasses 90 Million Patient Journeys and 270 Million Studies within its Network
03/06/2026
Network Expands to More Than 2,300 Healthcare Partner Sites, Advancing the Company's Strategic Network-Growth MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “ [...]
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
03/06/2026
FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that it has entered into a warrant exercise agreement with existing accredited [...]
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
03/06/2026
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability [...]
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
03/06/2026
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the Genital Psoriasis [...]
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
03/06/2026
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on [...]
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
03/06/2026
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
SweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This Summer
03/06/2026
As Atlanta welcomes the world for a summer of international soccer, SweetWater is bringing fans together through citywide activations, stadium experiences, watch parties and exclusive collaborations. ATLANTA, June 03, [...]
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
03/06/2026
SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) [...]
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
03/06/2026
Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, [...]
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
03/06/2026
Noctrix Health acquisition validates Angelini Ventures’ strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3 rd June 2026 – [...]
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
03/06/2026
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 Novel [...]
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
03/06/2026
- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates prostate cancer as a [...]
RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities
03/06/2026
LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“ RadNet ”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network [...]
Mammogen Secures Up to $30 Million Series A Financing Backed by Leading U.S. Public Retirement System to Advance Blood-Based RNA Breast Cancer Detection Platform
03/06/2026
Institutional financing supports pivotal prospective clinical advancement and commercialization of Mammogen’s RNA-powered molecular diagnostics platform NEWPORT BEACH, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Mammogen [...]
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
03/06/2026
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of [...]
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2026
NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 [...]
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
03/06/2026
Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleeding, infection, [...]

Pages